Join an information session to learn more about the XLR8 program, applications, and how your company could benefit from participating.
Upcoming Information Sessions: Wednesday, February 4th 5:00pm – 5:30pm – Register here Wednesday, February 13th 12:00pm – 12:30pm – Register here
Program Dates: Applications open: January 22nd Applications close: February 18th Program starts (weekly virtual): March 16th S26 Open* (in person): April 13th – April 16th Program continues (biweekly virtual): April 20th – October 2nd S26 Close (in person): October 6th – 8th *Dates subject to change
A program for scale-ready companies seeking the capital, experience, and validation to move to the next level.
Helping founder/CEO’s tell an investment story, find experienced executives, and sign partner deals that matter most to investors.
Helping Founders
tell the right story to the right investors in the room
Matching Projects
to validate solution and fuel health system innovation
Providing Expertise
to fill out the C-suite with growth-stage executives
Company Qualifications
XLR8 PBC is designed for emerging health and life science companies that are preparing to scale. Ideal applicants have a validated product or solution, early traction in the market, and are seeking strategic partnerships, mentorship, and investor connections to accelerate their growth.
Companies seeking to participate in in the XLR8 PBC program should fall into one of following categories:
-Virtual Care -Digital Health -Health & Wellness -Payor Tech -Provider Tech -Medical Devices
Not open to regulatory pre-approval devices or therapeutics. May consider post-approval with support.
Abaca Requirements
Qualified companies are considered to be Abaca level 6 emerging to 7, as defined on the Abaca website. Companies will be required to self-certify that they meet this requirement.
NXgenPort(MN) NXgenPort has developed an implanted “Smart Port” for Care-at-Home monitoring, designed to alert physicians of early signs of infection. This breakthrough technology enhances patient outcomes while reducing hospitalizations.
Kinisi Inc. (CA) Kinisi Inc. is revolutionizing joint health with Kinisi Motion™, a deep-tech platform leveraging AI, biomechanics, and orthopedic expertise to predict, prevent, and manage knee injuries. Their flagship product, Kinisi Knee™, accurately forecasts ACL instability, helping to reduce injuries and long-term arthritis.
The Patient Company (AZ) The Patient Company is transforming patient movement with SimPull, an innovative platform that automates patient transfers, significantly reducing injury risks for both healthcare staff and patients. SimPull has proven to be cost- and time-effective, helping hospitals enhance safety and efficiency.
TendoNova (GA) TendoNova markets an FDA-cleared microinvasive device for treating orthopedic issues like tendinopathy. Their technology bridges a major treatment gap between physical therapy and surgery for chronic pain.
A.I.VALI(Toronto) Based out of Toronto, A.I.VALI is a med‑tech SaaS delivering AI‑driven, real‑time endoscopy image analysis and reporting to streamline clinical workflows.
Hexoskin (Montréal,) Based in Montréal, Hexoskin develops smart wearable garments that continuously monitor ECG, respiratory, activity, and sleep via clinically validated sensor‑embedded shirts.
Resuture (Phoenix) Phoenix based company Resuture developed advanced, AI‑enhanced vascular models and online platforms to elevate surgical training and reduce patient and system risk.
Resuture (Phoenix) Phoenix based company Resuture developed advanced, AI‑enhanced vascular models and online platforms to elevate surgical training and reduce patient and system risk.
NeruoCatch(British Columbia) British Columbia based NeuroCatch, developed a portable EEG‑based platform to rapidly and objectively assess cognitive brain function via “brain vital signs” at the point‑of‑care.
